Cite
HARVARD Citation
Cortot, A. et al. (2020). Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study. European journal of cancer. pp. 27-36. [Online].